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Abstract 
Keratinocyte carcinomas (KCs) are the most common cancers globally. Ultraviolet light 
is the key risk factor for these cancers but sunscreen has proven ineffective in their 
prevention, indicating a need for new prophylactic agents. Chronic elevation of high 
molecular weight (HMW) tissue hyaluronan (HA) in skin is linked to tumor resistance in 
the naked mole rat. To directly assess the role of this polysaccharide in resistance to 
keratinocyte tumors, a HMW HA phosphatidylethanolamine (HA-PE) formulation that 
penetrates skin and accumulates as coats around keratinocytes was prepared. The tumor 
resistance properties of the HA-PE formulation were tested in a mouse model of UVB-
induced KC (Hr-/- Ptch+/-). HA-PE significantly reduced the number of visible lesions 
per mouse compared to the control groups. None of these lesions were neoplastic; in 
contrast, approximately 20% (7/34) of lesions were neoplastic in control groups. These 
results show that HA-PE protects against UVB-induced keratinocyte transformation, 
suggesting that HA-PE may be an effective preventative therapy for KC.  
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Chapter 1  
INTRODUCTION 
One in three cancers diagnosed is a non-melanoma skin cancer (NMSC), which are 
largely comprised of keratinocyte carcinomas (KCs) [1] and KC incidence is increasing 
[2]. Tanning for cosmetic purposes continues to rise in prevalence [3] despite its clear 
link to cancers of the skin [4]. Although mortality rates with KCs are low, these have a 
significant effect on patient morbidity due to 80% of these lesions occurring on sun 
exposed sites such as the face [5, 6] and are a health care burden. Current preventative 
treatments are ineffective [7], indicating a need for novel preventative agents. 
1.1 Anatomy of the Skin 
The skin is organized into three layers: the outermost epidermis, the dermis, and the 
innermost hypodermis [8]. The epidermis is avascular and receives nourishment via 
indentations of the dermis into the epidermis called dermal papillae (Kamel, 2000). The 
epidermis varies in thickness across species: for example, humans generally have a 
thicker epidermis than mice. Thickness also varies within an organism based on location, 
with the eyelids in humans having fewer keratinocyte layers than the soles of the feet [8]. 
The epidermis, composed of 80% keratinocytes, is organized into keratinocyte layers 
depending on their level of differentiation (Figure 1).   
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Figure 1: Layers of the Human Epidermis 
The epidermis, separated from the dermis by a basement membrane, is composed largely of keratinocytes 
organized into layers based on proliferation rates as well as morphology. Image taken from [9]. 
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The basal lamina, or basement membrane is between the epidermis and dermis. Basal 
keratinocytes in the stratum basale are the progenitor cells for the upper layers or the 
epidermis and these actively proliferate. Melanocytes are integrated into this basal layer 
and produce melanin, which chemically protects skin cells from damaging ultraviolet 
radiation [10]. Basal cell carcinomas originate from keratinocyte-precursor stem cells of 
the follicular bulge [11, 12]. Basal keratinocytes can also differentiate into fibroblasts in 
the presence of interleukin-1 (IL1), activin, and transforming growth factor-β (TGFβ) 
[13]. Distal to the stratum basale is the stratum spinosum, so named because the 
keratinocytes have a “spiny-spindly” structure; these keratinocytes are more 
differentiated in terms of an increasingly cornified cell envelope and limited motility than 
the basal keratinocytes, and are less likely to be actively proliferating. Above this layer is 
stratum granulosum containing the keratinocytes that are no longer capable of 
proliferating [8]. Finally, in the outermost layer of the skin (stratum corneum), the 
keratinocytes are terminally differentiated, have lost their organelles, and are no longer 
considered alive (Rheinwald & Green, 1977). In addition to keratinocytes and 
melanocytes, the epidermis also contains Langerhans cells which contribute to the 
immunologic function of the skin, making it a secondary lymphoid organ (Edelson & 
Fink, 1985). 
The skin has a variety of functions owing to its elegant structure and varied cell type. 
Skin functions as a physical barrier protecting against friction, infection, and moisture 
loss. This barrier is not completely impenetrable and serves as a site for the transport of 
carbon dioxide, nitrogen, and oxygen for the epidermis [14]. Thermoregulation is 
accomplished by the skin via eccrine sweat glands, muscles of hair erection, the capillary 
beds of the dermal papillae, and by adipose tissue in the hypodermis [15]. One integral 
molecule that contributes to the many functions of skin is hyaluronan.  
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Figure 2: Chemical Structure of Hyaluronan 
Hyaluronan (HA, hyaluronic acid) is a repeating polymer of N-acetyl-D-glucosamine and D-glucuronic 
acid. HA exists in nature as an unbranched and unsulphated polymer. Image taken from: [16].  
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1.2 Hyaluronan 
Hyaluronan (HA) is an unbranched, unsulphated, polymer of repeating disaccharides of 
N-acetyl-D-glucosamine (GlcNAc) and D-glucuronic acid (GlcA) that can be repeated up 
to 30,000 times for a molecular weight ranging from 105 to 107 kDa [17, 18]. HA is an 
elastic  matrix for tissue remodeling due to its ability to bind large amounts of water and 
form viscous gels at relatively low concentrations [19]. HA is synthesized by the HA 
synthases: HAS1, HAS2, and HAS3 [20]; HAS1 and HAS2 produce HA ranging from 
200-2000 kDa and HAS3 generates smaller HA of 100 to 1000 kDa [21, 22]. Native, or 
high molecular weight (HMW), HA exists as larger polymers (>500 kDa) that decrease 
inflammation and tissue fibrosis [23, 24]. HA is degraded enzymatically by 
hyaluronidases; when degraded, low molecular weight (LMW, <100 kDa) HA increases 
inflammation  [23].  
A constitutively expressed receptor for HA is cluster of differentiation 44 (CD44), which 
is encoded by a single gene with ten constant and ten variant exons [25, 26]. CD44 is 
essential for the retention of an HA pericellular matrix surrounding keratinocytes [27] 
The binding of HA by CD44 regulates various functions and differentiation [28]. The 
receptor for hyaluronan mediated motility (RHAMM) is the second major  receptor for 
HA and is expressed in dermal fibroblasts [29] but not in immortalized keratinocytes 
[30]. Epidermal keratinocytes produce HA and deposit it extracellularly in the suprabasal 
layers and intracellularly in the basal layer [31]. Fifty percent of HA in the human body is 
in the skin [32] where its hydroscopic properties maintain moisture required for its barrier 
function [33]. HA is ubiquitous in the skin: it exists freely in the extracellular matrix as 
well as in organized cell- and protein- associated pericellular coats [34, 35].  
Skin HA also functions as a signaling molecule [36]. Through the membrane-associated 
CD44 and RHAMM, the latter of which also has intra-cellular forms, HA is involved in 
cell migration and differentiation during inflammation and wound healing [37].  
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1.3 Keratinocyte Carcinoma 
Keratinocyte carcinomas (KCs) include basal cell carcinomas (BCCs) and squamous cell 
carcinomas (SCCs) in a 4:1 ratio [2]. These tumors cause cosmetic and sometimes 
functional impairment impacting patient morbidity due to their location on the highly 
sun-exposed face and neck [38]. Recorded KC is the most commonly reported cancer 
globally; however, the actual incidence is difficult to estimate as few registries routinely 
collect this data [5]. Mortality rates are estimated to be low for both types but SCC is 
twelve-fold more fatal than BCC [39] as SCCs have a greater tendency to metastasize 
[40].   
1.3.1 Prevention of KC 
There is increasing evidence that current sun protection mechanisms beyond exposure 
avoidance and covering with clothing are insufficient to prevent keratinocyte tumors. 
Several studies have linked high risk populations, such as those who work outdoors, to a 
lack of perceived risk in KC and thus a lack of sunscreen use [41, 42]. However, a study 
with high-risk organ transplant recipients showed that increased education improved 
sunscreen behavior but did not significantly affect skin cancer incidence [43].  A recent 
multi-database review of randomized controlled clinical trials of sunscreens found no 
difference in BCC or SCC incidence between participants who used daily sunscreen to 
those who used sunscreen at their discretion, demonstrating the lack of capability of 
current sunscreens to prevent KCs [44].  
As far as current preventative agents are concerned, sunscreens have been shown to be 
ineffective in preventing BCC [7]. There is evidence that correct application can prevent 
SCC [45] but sunscreen use is lower than the ideal [46]. 
1.4 Ultraviolet Radiation 
Ultraviolet radiation (UVR) exposure, most often from the sun, is the most important risk 
factor for KC (Matsumura & Ananthaswamy, 2004). SCC risk is strongly related to 
cumulative sun exposure, whereas the timing, pattern, and amount of exposure influences 
BCC risk (B. K. Armstrong & Kricker, 2001).  
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Ultraviolet radiation (UVR) is subdivided into three categories: UVA (320-400 nm), 
UVB (280-320 nm), and UVC (100-280 nm) [47]. UVA light penetrates the epidermis 
and into the dermis while UVB mainly penetrates into the epidermis [48] with 10-15% of 
UVB reaching the dermis [49]. Very little UVC light reaches the Earth’s surface due to 
the filtering effects of the ozone layer [48] but is still a concern in areas of the world 
where this protective layer has been depleted [50].  
Protective adaptation of skin to UVR includes hyperplasia in the epidermis and 
thickening of the stratum corneum (Pearse, Gaskell, & Marks, 1987). This increase in 
proliferation is maximal 48 hours after UVR exposure and can last for up to two weeks 
(Ouhtit et al., 2000). Melanogenesis, or increased production of melanin, occurs as a 
result of UVR and provides increased protection of DNA (deoxyribonucleic acid) against 
UVR exposure as it collects over the nuclei of keratinocytes and absorbs the ultraviolet 
radiation [51].  
1.4.1 Ultraviolet DNA Damage 
DNA bases are a major chromophore of UVR in the skin; they maximally absorb 
between 260 and 265 nm causing alterations in nucleotide structure [52]. The 
predominant lesions caused by UVB exposure are cyclo-butane pyrimidine dimers 
(CPDs) and pyrimidine-pyrimidone 6-4 photoproducts (6-4 PPs), making up 65% and 
35% of DNA lesions, respectively [53, 54]. UVA light is less mutagenic than UVB but 
tends to promote reactive oxygen species (ROS) formation, which results in oxidative 
DNA damage [55] and formation of dihydro-8-oxyguanosine (8-oxoG) [56]. This DNA 
damage is found in the basal and suprabasal keratinocytes and the Langerhans cells of the 
epidermis [57].  
UVB-induced mutations in keratinocyte nucleic acids, if not repaired but preserved and 
passed on to subsequent keratinocyte generations, can result in keratinocyte neoplastic 
transformation [58]. 
UVR also induces mutations in proteins such as p53, a tumor suppressor that either 
blocks progression of cells through the mitotic cycle after damage, allowing more time 
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for DNA repair [59] or promotes apoptosis. Roughly 50% of BCCs and 90% of SCCs 
from human patients have a p53 mutation [60-62].  
1.4.2 Immune Response to Ultraviolet Radiation  
Ultraviolet light is an example of sterile injury, which is defined as a cause of 
inflammation that does not occur as a result of microbial stimuli [63] . Erythema is a 
redness in the skin that occurs because of the dilation of cutaneous blood vessels and is 
the initial inflammatory response to UVR [64]. Erythema is biphasic: there is an initial 
immediate erythema that disappears after 30 minutes and a second occurrence that peaks 
between 24 and 48 hours after exposure (Logan & Wilhelm, 1963). This response is used 
to standardize UVR dose in terms of the lowest dose that will cause this reaction and was 
so named the minimum erythemal dose (MED) [65].  
The average HA molecular weight is decreased by a factor of 10 after UVB irradiation in 
vivo [66]. The release of fragments of HA from the extracellular matrix (ECM) is 
associated with the sterile inflammatory response [63, 67-69]. HA fragments of low to 
intermediate size activate macrophages [70].  Macrophages bind and phagocytose 
apoptotic cells [71] and the number of macrophages increases in skin after UVB 
treatment [72]. N-acetyl-β-D-glucosaminidase (NAG) is predominantly produced by 
macrophages and has been utilized to detect macrophage activation and accumulation 
[73, 74]. 
UVR-induced macrophages are a major source of epidermal IL-10, which downregulates 
the type 1 helper T cell (Th1, cellular) immune responses [75]. This observation led to 
the theory that macrophages mediate the downregulation of the immune system after 
UVR exposure [76]. There are two subtypes of macrophages: during activation, 
macrophages become polarized into either the classical M1, which produces pro-
inflammatory cytokines, or the M2, which secrete anti-inflammatory cytokines that 
suppress immune responses [77]. M2, and not M1, macrophages promote angiogenesis in 
vivo [78] and increases in M2 macrophages are associated with poor prognosis in human 
cancer [79].  
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1.4.3 UVR-Induced Immunosuppression 
Langerhans cells (LCs) make up 3-5% of the cells in the epidermis and are the only 
constituent antigen presenting cell (APC) present [80]. Exposure of LCs to UVB converts 
them from immunologically potent APCs to tolerogenic APCs: stimulation of Th1 
(effector) cells is reduced while the ability to stimulate a type 2 helper T cell (Th2) 
response remains (suppression) [81]. This observation may be due to the action of 
increased interleukin-10 (IL-10) after UVR treatment [82]. Yagi et al. generated a Th2 
like cell line that suppressed contact photosensitivity in an IL-10-dependent manner [83]. 
IL-10 mediates the systemic suppression of cellular antigen presentation after UVB 
exposure [84].  
UVB-damaged LCs expressing thymine dimers, a subset of CPD, migrate to the lymph 
node 1 hour after exposure, reducing their numbers in the epidermis [85]. APCs stimulate 
T cells and epidermal Langerhans cells have a reduced ability to stimulate T cells 
following UVB exposure [86]. This reduced function in LCs after UVB treatment has 
been shown have a reduced T-cell proliferative response [86].  
1.4.4 Immune System and Cancer 
As early as 1909, it was suggested that the immune system could be protective against 
cancer [87]. Kripke showed that induced tumors are highly immunogenic and are only 
transplantable to immunosuppressed hosts [88] and later found that UVR-induced tumors 
could only grow in the primary host due to this UVR-induced immunosuppression [89]. 
UVR causes suppression of not only the local but the systemic immune system by the 
release of circulating cytokines  mediated by UVR-stimulated keratinocytes [90, 91].  
Skin cancers caused by UV radiation in mice are highly antigenic, and increased 
susceptibiltiy to KCs in patients undergoing imunnosupressive treatments suggests that 
this is also true in humans [92].  White transplant recipients experience a 65 to 250-fold 
and 16-fold increased risk of SCC and BCC, respectively, compared to the non-
transplanted population [93, 94]. Patients with HIV/AIDS or chronic lymphocytic 
leukaemia also have aggressive SCCs [95, 96]. With so many populations at increased 
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risk of KC, mice are an excellent model of high cancer susceptibility. However, other 
rodents such as the naked mole rats are unexpectedly resistant to all cancers.  
1.5 Naked Mole Rats 
The naked mole rat, or Heterocephalus glaber lives up to 30 years in captivity [97]; this 
lifespan is seven-fold  greater than that predicted by their mass [98]. Naked mole rats do 
not experience declines in functions such as reproduction as they age [99]. Most 
remarkably, naked mole rats show resistance to cancer [100, 101].  
In the over 40 years that naked mole rats have been in captivity, only four incidences of 
cancer have been reported [101, 102]. This is in contrast to C57BL/6 mice, the majority 
of which die with neoplastic lesions [103]. The resistance of naked mole rats is of 
particular interest because naked mole rats live in an environment of hypoxia yet are 
tolerant to low partial pressures of oxygen (hypoxia) and high amounts of carbon dioxide  
[104, 105], which are factors thought to promote tumor aggression in humans.  
Naked mole rat skin has an increase in concentration of high molecular mass (HMM) 
hyaluronan (HA) relative to other tissues. This increase most likely evolved to confer the 
elasticity required in skin for life underground [106]. Tian et al. attributed naked mole rat 
cancer resistance to the accumulation of hyaluronan [106]. Naked mole rat skin 
fibroblasts accumulate HA due to increased production and decreased degradation of HA 
relative to the highly cancer-prone mouse in dermal fibroblasts cultured from both 
species [106].  
Naked mole rat HAS2 has two amino acid substitutions relative to the otherwise well 
conserved gene [106], resulting in hyaluronan was of a greater molecular weight than that 
observed in mice [106]. Silencing of HAS2 or overexpression of the HA-degrading 
enzyme hyaluronidase 2 (HYAL2) in naked mole rat skin fibroblasts led to susceptibility 
to malignant transformation and tumorigenesis in mice [106]. This data from the cancer-
resistant, long-lived naked mole rat links HA to skin tumor resistance. 
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1.6 HA-PE 
Hyaluronan greater than 50 kDa in size does not easily penetrate the epidermis due to 
size limitations, the strong hydrophilic structure of HA, and the hydrophobic properties of 
the stratum corneum of skin [107]. Therefore, to enrich skin by topically applying HMW 
HA (e.g. >500 kDa) requires modification of the hydrophilic nature of HA. Symonette et 
al. modified HMW HA to permit penetration into skin and to promote the formation of 
HA coats around keratinocytes and dermal cells.  HA without the phospholipid 
accumulated on the stratum corneum [108]. Penetrance of the stratum corneum by HA-
PE is likely due to the conferred apolarity of the phospholipid molecule [109]. 
With this formulation and its proven skin-pentrating and coat-forming properties, I was 
able to proceed with my goal of reducing UVB-induced neoplasia.   
1.7 Mouse Model 
1.7.1 Patched1 and BCC Susceptibility 
Basal cell nevus syndrome (BCNS), or Gorlin syndrome, is caused by an inherited defect 
in one copy of the Ptch gene that is dominant over the wild-type version. Patched1 (Ptch) 
is part of the hedgehog (Hh) pathway, and inhibits the downstream smoothened (Smo) 
when Hh signal is absent, preventing pathway activation and inhibiting the transcription 
of targets of the Hh pathway such as glioma associated oncogene (Gli) transcription 
factors and other target genes such as cyclin D1/D2 [110].  Mutations in Ptch result in 
sustained activation of target genes, some of which promote the development of skin 
cancer. In a study of humans with BCNS, 80% of Caucasian patients and 38% of black 
patients developed at least one BCC, with the mean age of the groups being 23 and 21, 
respectively. In the same study, the number of BCCs per patient ranged between one and 
over 1000 [111]. Mutations in Ptch have been found in up to 68% of sporadic BCCs 
[112]. Loss of Ptch has also been reported as an early event in SCC pathogenesis [113].  
In CB57BL/6 mice model of keratin tumor susceptibility (The Jackson Laboratory), the 
Ptch gene has been inactivated by replacing exon 1, which includes the start codon, and 
all of exon 2 with a beta-galactosidase (lacZ) reporter and a neomycin resistance gene. 
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This generates a larger polymerase chain reaction (PCR) product (479 base pairs, bp) 
than the wild-type Ptch (200 bp) [114]. Mice homozygous for this inactivated form (Ptch-
/-) die between embryonic days 9 and 10.5 due incomplete neural tube formation and 
cardiac malfunction (Goodrich, Milenković, Higgins, & Scott, 1997). Ptch heterozygous 
(Ptch+/-) mice are viable while exhibiting defects consistent with BCNS, such as 
increased susceptibility to BCC development in response to UVR [115]. In this mode, 
there is an absence of tumors on sites lacking Smo expression, such as the ears and tails 
[12].  
Ptch+/- mice have become a standard for studying UVB-induced BCCs; however, most 
Ptch+/- mice are bred on a CB57BL/6 haired mouse background and hair removal can 
cause skin irritation and inflammation, as well as interfere with the topical application of 
preventative treatments, making mice lacking hair ideal for this experiment.  
1.7.2 Hairless Mice and SCC Susceptibility 
The hairless (Hr) gene is highly expressed in the skin [116] where it intereacts with 
vitamin D receptor (VDR), which regulates cutaneous inflammation [117]. The hairless 
allele is an autosomal recessive mutation generated via the insertion of a modified 
retrovirus genome integrated into exon 6 of the Hr gene, which results in abnormal 
splicing in 95% of transcripts [118]. The first coat of hair in Hr homozygous mice (Hr-/-) 
develops normally but begins to shed at two weeks of age, with complete hair loss at 3 
weeks [119]. Hairless mice are ideal for skin studies, as hair removal and any associated 
inflammation are avoided. SKH-1 mice are more susceptible to UVB-induced skin 
cancer, especially SCC, than their haired counterparts [120, 121]. Hairless mutations in 
SKH-1 confer susceptibilty to UVB-induced tumorigenesis in a nuclear factor-κB-(NF-
κB) dependent manner [122].   
1.7.3 Hr-/- Ptch+/- Mouse Model of Keratinocyte Tumor Susceptibility 
Xu et al. (2014) genetically engineered hairless SKH-1 mice that also express the mutant 
version of Ptch  to result in a genotype of Hr-/- Ptch+/-.  This group compared the 
response of these mice to 26 weeks of UVB exposure with that of their haired 
counterparts (Hr+/+ Ptch.  Hairless Patch heterzygotes developed significantly more 
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BCCs and SCCs than haired (shaved) littermates (Xu et al., 2014). Tumor induction 
occurred 10 weeks earlier in the hairless mice compared to the haired [123]. Additionally, 
there was a five-fold increase in overall tumor load (tumors per mouse) in hairless 
relative to haired mice [123]. Both groups developed benign papillomas, as well as highly 
differentiated SCCs, and BCCs, but the hairless also developed highly invasive SCCs, 
trichoblastomas, and rhabdomyosarcomas [123]. In contrast to the haired transgenic 
mice, Hr-/- Ptch+/- mice showed no significant difference in tumor load between genders 
allowing use of both males and females for the present study [123]. 
The increased predisposition  of Hr-/-Ptch+/- to tumor formation was attributed to a more 
robust inflammtory response than observed in Hr+/+Ptch+/- mice [123]. Use of 
sulfasalazine (SSZ), an NF-κB inhibitor, significantly decreased both SCCs and BCCs in 
murine models, was acompanied by a decrease in a cyclooogyenase 2 (COX-2) and B-
cell lymphoma 2 (Bcl2) in the SSZ treated group, as well as an increase in apoptosis and 
a decrease in proliferation response, relative to the untreated Hr-/-Ptch+/- group [123]. 
Additionally, UVB-induced, inflammation-related genes were attenuted by SSZ treatment 
in perilesional skin in Hr-/-Ptch+/- mice [123]. 
1.7.4 Benign Skin Lesions of the Hr-/-Ptch+/- Model 
Benign lesions considered in this study include cysts, keratin granulomas, dermatitis, and 
follicular hyperplasia. A cyst is a closed sac that is separated from the nearby tissue by a 
distinct membrane containing fluid inside. These are non-cancerous and can result from 
infection, the clogging of sebaceous (oil) glands, or the presence of foreign bodies [124].  
A keratin granuloma is a non-cancerous, organized collection of macrophages that have 
formed around keratin when the immune system perceives it as a foreign body [125]. 
Dermatitis is inflammation of both the dermis and the epidermis but is not linked to an 
increase or decrease in skin cancer susceptibility [126]. Follicular hyperplasia is an 
increase in the number of cells in the hair follicle as a result of increased reproduction 
rate [127].  
Benign precursor lesions of SCCs also occur and include actinic keratosis and squamous 
cell carcinoma in situ (Bowen’s disease) and both are considered premalignant [128] . 
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Keratoacanthomas have clinical and histological similarities to well differentiated SCC 
and are characterized by rapid onset, progression, but regression within months of their 
appearance (Beham, Regauer, Soyer, & Beham-Schmid, 1998). They occur when cells of 
the pilosebaceous glands within a hair follicle grow abnormally and are considered a low-
grade skin cancer (Beham, Regauer, Soyer, & Beham-Schmid, 1998). Papillomas of the 
squamous cells are generally benign but can progress if induced by carcinogens such as 
UVB or chemicals. They result from infection with human papilloma virus (HPV) [129].  
1.8 Rationale, Hypothesis, and Objectives 
The lack of a reliable means of preventing UVB-induced neoplasias reveals a clinical 
need for a new preventative agent that would be effective against BCC, as well as SCC.  
The prevalence of KC is expected to continue increasing due to the global shift towards 
an increased ageing population [130] as approximately 80% of cases occur in persons 60 
years of age or greater [131]. Age-dependence of these tumors is thought to be 
contributed in by their slow development with damage from childhood only becoming 
apparent later in life [132].  Additionally, the age-dependent depletion of hyaluronan 
from the skin correlates with increased skin cancer risk observed among the elderly [31]. 
Given the tumor resistance in the naked mole rat due to increased HA and our ability to 
increase HA in the skin using the HA-PE formation, I hypothesized that the application 
of HMW HA will mimic naked mole rat cancer resistance mechanisms in a mouse model 
of ultraviolet light-induced KC susceptibility.  
The objectives for this dissertation were as follows:  
1. Establish the colony for the mouse model of UVB-induced skin cancer 
susceptibility.  
2. Induce tumors with UVB radiation in the genetically modified mice across the 
experimental HA-treated group as well as the untreated controls.  
3. Compare histology of palpable growths between the HA-treated and untreated.  
4. Compare hyperplasia in the HA-treated group with the untreated controls.  
5. Compare inflammation in the HA-treated group with the untreated controls.  
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Chapter 2  
2 METHODS 
2.1 Maintaining, Breeding, and Characterization of Mice 
2.1.1 Animal Housing 
Mice were individually caged in a temperature-controlled environment with a twelve-
hour light/dark cycle and fed PicoLab mouse diet (LabDiet, St. Louis, MO, United 
States) ad libitum. All experiments were approved by and compliant with the standard 
operating procedures of the Animal Use Subcommittee at the University of Western 
Ontario, Canada (2009-060). 
2.1.2 Breeding 
Breeding for the chronic study was performed as described previously [123]. Mice were 
given one week upon arrival to the animal facility to acclimate prior to breeding. Male 
Ptch+/-/C57BL/6 mice (Stock number 003081, Jackson Laboratory, Bar Harbor, ME, 
United States) were crossed with female SKH-1 hairless mice (Strain Code 477, Charles 
River Laboratories, Wilmington, MA, United States) as shown in Figure 3. Mice of the 
F1 were genotyped for the Patched 1 mutation (Ptch+/-) and those carrying the mutation 
were bred with one another. Mice of the F2 that were both hairless and carriers of the 
Patched 1 mutation (Ptch+/-) were utilized in the study.  
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Figure 3: Mouse Breeding Scheme 
The probability of obtaining each genotype of the F2 offspring is detailed in Table 1 considering the 
lethality of Ptch-/-; mice with two mutant versions of Patched1 are embryonic lethal [114].   
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Table 1: Predicted F2 Offspring Outcomes 
F2  
(F1 x F1) 
Hr Pt hr Pt Hr pt hr pt 
Hr 
HrHr PtPt Hrhr PtPt HrHr Ptpt Hrhr Ptpt 
Pt 
hr 
Hrhr PtPt hrhr PtPt Hrhr Ptpt 
hrhr Ptpt 
(2/16) Pt 
Hr 
HrHr Ptpt Hrhr Ptpt HrHr ptpt Hrhr ptpt 
pt 
hr 
Hrhr Ptpt 
hrhr Ptpt 
(2/16) 
Hrhr ptpt hrhr ptpt 
pt 
 
Haired (9/16) Hairless (3/16) 
Embryonic 
Lethal 
(4/16) 
A Punnett square outlining the predicted genotypes (lettering) and phenotypes (box shading) of the F2 
generation. The parental cross was between a haired heterozygous (hr +/+ Ptch +/-) CB57BL/6 male mouse 
and a hairless wild-type (hr-/- Ptch +/+) SKH-1 female mouse. Haired (hr+/-) heterozygous (Ptch+/-) SKH-
1 CB57BL/6 mice of the F1 generation were bred together to get the F2 generation.  The haired (Hr) allele 
(gray box) is dominant over the hairless (hr) allele. Mice homozygous for the mutant version of Patched1 
(pt) are embryonic lethal (black box). 
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Eye color can differ between F2 Hr-/- Ptch+/- mice in this model due to the recessive red 
(pheomelanin) eyes from the SKH-1 and the dominant brown (eumelanin) eyes from the 
CB57BL/6 in the parental generation. Since melanin provides photoprotection from 
ultraviolet light [133], mice were organized in groups with equal distribution of eye 
colors to control for any potential differences in natural resistance to damage by 
ultraviolet light. 
 More than half of the mice had brown eyes and both eye colors were evenly distributed 
across groups to control for any protective effects pigmentation may confer within 
groups. These proportions were maintained as the group sizes became reduced (Table 2). 
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Table 2: Chronic Study Mouse Eye Color Distribution 
 Actual Eye Color Distribution Ideal Distribution 
 Brown Red Brown Red 
No Cream 
Control (NCC) 
3 (60%) 2 (40%) 3 (60%) 2 (40%) 
Vehicle Cream 
Control (VCC) 
5 (71%) 2 (29%) 4 (57%) 3 (43%) 
HA-PE 4 (50%) 4 (50%) 5 (63%) 3 (37%) 
Presented in Table 2 are the ideal, or evenly distributed, and actual eye color distributions across the mice 
that completed the treatment period across the three groups. Eye color here is being used as an indicator of 
pigmentation, which has the potential to confer increased resistance if higher in certain groups. Variation in 
pigmentation is the results of the parental cross of the Patched1 wildtype hairless SKH-1 mice with red 
eyes and the Patched1 heterozygote haired CB57BL/6 mice with brown eyes. 
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2.1.3 Tail DNA Isolation 
When mice were between 14 and 21 days of age, tissue samples smaller than 0.5 cm were 
taken from the tails of mice and stored at -20oC until genotyping was performed. Tissue 
was lysed overnight at 55oC using 350 µL lysis buffer (1 M Tris, 0.5 M EDTA, 10% 
SDS, 5 M NaCl, pH 8) and 300 µg proteinase K (Roche, Mannheim, Germany). The 
following day, samples were spun at 208 x g for 10 minutes at room temperature. The 
supernatant was transferred to new tubes containing 500 µL isopropanol, and tubes were 
inverted 5 times to mix. Samples were spun at 208 x g for 10 minutes at room 
temperature. The supernatant was discarded, and the pellet was washed with 500 µL of 
ethanol (-20oC). Tubes were spun at 208 x g for 10 minutes at room temperature, washed 
with ethanol (-20oC) again, and then spun at 208 x g for 5 minutes at room temperature. 
Supernatant was discarded, and DNA pellets were left to air dry at room temperature 
overnight in open microcentrifuge tubes. The next day DNA was resuspended in 100 µL 
of ddH2O and incubated at 55
oC for 15 minutes to dissolve the pellet. 
2.1.4 Determining DNA Concentration 
DNA concentration was determined using NanoDrop (ThermoScientific, Waltham, MA, 
United States). The NanoDrop apparatus was blanked using 2 μL of ddH2O. 2 μL of each 
DNA sample was loaded onto the NanoDrop machine to find DNA concentration, which 
was given in ng/μL. The ratio of the absorption at 260 nm over the absorption at 280 nm 
varied between 1.85 to 1.97. Samples were diluted in ddH2O to make 100 μL of 50 ng/μL 
DNA in ddH2O. 
2.1.5 Patched1 (Ptch) Genotyping 
Genotyping to confirm patched heterozygosity was performed using the protocol 
provided on the Jackson Website [134] and outlined below.  
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Table 3: Primers for Patched1 Genotyping 
Version 
of Ptch 
Forward (5’ to 3’) Reverse (5’ to 3’) 
Wildtype CTGCGGCAAGTTTTTGGTTG AGGGCTTCTCGTTGGCTACAAG 
Mutant GCCCTGAATGAACTGCAGGACG CACGGGTAGCCAACGCTATGTC 
Primer sequences and protocol to determine Ptch genotype were obtained from the Jackson Labs website 
[134].  
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Primers (Table 3, Invitrogen, Waltham, MA, United States) were dissolved in ddH2O to 
a concentration of 100 nmoles/mL. For the PCR reaction, each tube contained 12.5 µL 
AmpliTaq Gold (ThermoFisher, Waltham, MA, United States), 1 µL of GC Enhancer 
(ThermoFisher, Waltham, MA, United States), 0.25 µL of each 100 nmole/mL primer 
solution, and 8.5 μL of ddH2O. To each tube 2 µL of mouse DNA was added. 
The PCR reaction was done as follows: 94oC for 1.5 minutes to start; cycle through 94oC 
for 30 seconds, 69oC for 1 minute, 72oC for 45 seconds, and repeat 35 times; finally, hold 
at 10oC. Amplified samples were separated by gel electrophoresis on a 1.5% agarose gel 
in 1X TBE (90 mM Tris-borate, 2 mM EDTA, pH 8.3) buffer. 50 μL of a 1 mg/mL 
aqueous solution of ethidium bromide was added to the gel solution and swirled to mix 
before pouring into the gel mold. Prior to loading, the gel was placed in the dock and 
submerged in 1X TBE buffer. In the first lane of each gel, a DNA ladder (ThermoFisher, 
Waltham, MA, United States) was applied. The ladder is prepared by adding DNA gel-
loading dye in a 10:1 ratio (ladder:dye). To make DNA gel-loading dye (10X), combine 
3.9 mL glycerol, 500 μL 10% (w/v) SDS, 200 μL 0.5 M EDTA and 0.025 g bromophenol 
blue, bringing to a final volume of 10 mL with ddH2O. 2 µL of DNA gel-loading dye was 
added to each PCR reaction tube and pipetted up and down to mix. 10 µL of amplified 
DNA with dye was applied per lane. The power supply provided 110 V to the gel for 1 
hour. The power supply was turned off and the gel was imaged using the Molecular 
Imager® Gel Dock ™ XR+ with ImageLab ™ Software (Universal Hood II, Bio-Rad 
Laboratories, Hercules, California, United States). The wild-type Patched1 allele forms a 
strand that is 200 base pairs in length and the mutant allele forms a strand 479 base pairs 
in length. Thus, a wild-type mouse will have one band corresponding with the ladder’s 
200 base pair band. Mice carrying the mutant Patched 1 allele will have a second band 
between the 400 and 500 base pair bands of the ladder. 
2.2 Treatment of Mice 
2.2.1 UVB Irradiation 
UV irradiation unit (Daavlin Co., Bryan, OH, United States) that was employed was 
equipped with a UVB Spectrum 305 Dosimeter to regulate dosage. The UVB source 
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consisted of four bulbs (PL-L 36W/06, Phillips, Amsterdam, Netherlands) that emit UVB 
(290-315 nm, 80% of total energy) and UVA (315-400 nm, 20% of total energy) with a 
peak emission at 313 nm; UVC was not permissible through the unit. The distance 
between the radiation source and the targets was kept between 6 and 8 cm. Irradiation 
dose was 180 mJ/cm2, which was previously found to be 3 times the minimum erythema 
dose (MED) [123]. Exposure time for this dose was 30 to 45 seconds. 
2.2.2 Preparation of HA-PE 
HA-PE cream (PCT CA270352, [135]) was prepared as previously described [108]. 
Briefly, 1.35mL of 1% (v/w) Sodium Hyaluronate Solution (500 kDa, Medical Grade, 
Lifecore Biomedical, Chaska, MN, United States) and 252 𝜇L of isopropanolol was 
mixed thoroughly with 1.35 mL of unrefined liquid soy lecithin (Soy Lecithin GT non-
GM IP, Imperial-Oel-Import, Germany) at room temperature.  Dry (3.78 mg) 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide (EDC) (Sigma, St. Louis, MO, United States) was 
added and mixed thoroughly. After mixing for 10 to 15 minutes, 3 mL of vehicle cream 
was added and mixed for an additional 5 minutes. A water-based cream (Mango Face 
cream, Aquatech, Toronto, Ontario, Canada) was used throughout the study as the vehicle 
for mixing with HA-PE or unaltered as the vehicle cream control. Both the HA-PE and 
vehicle creams were stored protected from light at 4oC. 
2.2.3 Treatment Program 
The weekly treatment regimen began when the mice were between six and seven weeks 
of age. The mice were separated into three groups:  a no cream control (NCC, n=7), a 
vehicle cream control (VCC, n=10), and the HA-PE experimental group (n=10). In the 
latter two groups cream was applied once daily Monday through Friday, inclusive. Daily 
application the three days prior to cream application was chosen as while HA-PE has 
been previously shown the greatest increase in epidermal HA relative to the HA-only 
control after 24 hours, HA is still in the epidermis after 72 hours, thus cream application 
on the weekend after UVB irradiation was not necessary [108]. On Thursday and Friday, 
all mice received 0.1 mg/kg buprenorphine, diluted to 0.02 mg/mL with sterile D-PBS 
(2.68 mM KCl, 1.50 mM KH2PO4, 137 mM NaCl, 8.10 mM anhydrous Na2HPO4, pH 
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7.4, Wisent Bioproducts, St. Bruno, Quebec, Canada), via sub cutaneous injection. This 
was followed by 180 mJ/cm2 UVB light. Cream was applied after irradiation for the 
appropriate groups. Mice in the NCC, VCC, and HA-PE groups followed the weekly 
treatment schedule as described above for 26 weeks. On the first day (Monday) of each 
week, all mice underwent a visual and tactile skin examination under anesthesia. During 
this time photographs were taken prior to cream application.  
The chronic study of the effects of HA-PE on UVB light-induced cancer took place over 
26 weeks. Both male and female hairless (Hr-/-) mice that also carried a loss of function 
mutation in Patched 1 (Ptch+/-) were used in this study. 
2.3 Tissue Sampling 
Mice were euthanized by carbon dioxide 24 hours after the last UVB irradiation of the 
26th week of treatment. Lesions/abnormalities were excised by 8 mm punch biopsy, or 
scalpel when necessary. Prior to excision, lesions were measured along the widest 
diameter using digital calipers (500-170-30, Mitutoyo, Aurora, IL, United States) 
equipped with a USB measurement data input unit (IT-012U, 00-17-30, Mitutoyo, 
Aurora, IL, United States) for direct input into Microsoft Excel (Microsoft, Redmond, 
WA, United States). Tumor-adjacent phenotypically-normal skin was excised in two 8 
mm punch biopsies of superior dorsal skin, centred on the midline (Figure 4).  
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Figure 4: Murine Tissue Sampling 
24 hours following the final irradiation, Hr (-/-) Ptch (+/-) mice were euthanized using CO2. Immediately 
following euthanization, two 8 mm punch biopsies were taken along the midline of superior dorsal skin. 
Superior dorsal skin was utilized as mice could interfere with inferior dorsal skin by biting, licking, or 
scratching. The punch biopsies were prepared for paraffin processing and the remainder of the superior 
dorsal skin was stored for biochemical assays.  
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Tissue samples and lesions were fixed in 10% neutral buffered formalin (33.3 mM 
NaH2PO4, 45.8 mM Na2HPO4, 1.33 M CH2O, pH 6.8; Sigma, St. Louis, MO, United 
States) for 24 to 48 hours. With gentle agitation, tissue samples are submerged in 70% 
ethanol for one hour; 95% ethanol/5% methanol for one hour; and four washes in four 
separate containers of absolute ethanol for one hour for the first two and 90 minutes for 
the second two. Samples are then immersed in xylene for one hour, twice; and then after 
which they were submerged in paraffin first for one hour at 58oC, twice.  Tissues are then 
embedded into paraffin blocks and cut into 5 µm sections.  
The remainder of the superior dorsal skin was placed in a microcentrifuge tube and then 
frozen using 70% ethanol and dry ice. These samples were then stored at -80oC. 
2.4 Histological Processing 
Paraffin processing, as well as hematoxylin and eosin staining, was performed by Carl 
Postenka at the London Regional Cancer Program. The following steps were all 
performed at room temperature.  
Paraffin was removed from the samples by submerging the samples three times in xylene 
for 5 minutes each time. The samples were then rehydrated by being dipped ten times in 
100% ethanol. This was repeated twice, with three containers of 100% ethanol in total. 
The slides were dipped ten times in 95% ethanol in ddH2Oand this was repeated with a 
second container of 95% ethanol. The samples were then dipped in 70% ethanol in 
ddH2O ten times, and then ten times in 40% ethanol in ddH2O. The slides were then 
dipped in ddH2O ten times and this was repeated with a second ddH2O container.  
The slides were submerged in hematoxylin (SH26-500D, FisherScientific, Waltham, MA, 
United States) for 18 minutes at room temperature. The slides were then washed with 
ddH2O until the rinsings were clear. The slides were then immersed in acid alcohol 
(11.65 mM HCl in 70% ethanol in ddH2O) 13 times, followed by 10 dips into ddH2O to 
wash.  
The slides were then submerged in Alkaline (Scott’s) Tap Water (20 mM KHCO3, 16.62 
mM MgSO4, 0.1% formalin, in ddH2O) for 30 seconds. This was followed by 5 dips in 
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95% ethanol in ddH2O. The slides were then put into alcoholic eosin (3801600, Leica 
Biosystems, Concord, Ontario, Canada) for 10 minutes.  
Slides were dehydrated by dipping four times in 95% ethanol twice and four times in 
100% ethanol twice. Slides were dipped ten times in xylene and this was repeated twice, 
three times total. The slides were mounted on glass coverslips using Cytoseal-60 (8310-
16, ThermoScientific, Waltham, MA, United States) and left to dry for a minimum of 16 
hours at room temperature prior to scanning.  
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2.5 Pathological Analysis 
Histopathology analysis of the hematoxylin and eosin stained lesion sections was 
performed by the Pathology Core at The Centre for Phenogenomics in Toronto, Ontario, 
Canada. Neoplasia was characterized by the presence of changes in cell morphology and 
clonal expansion, as well as larger nuclei and mitotic figures; lesions were identified as 
hyperplastic by the presence of increased number of cell layers relative to mouse 
standards, and acute and chronic inflammation was identified by the presence of 
neutrophils and lymphocytes, respectively [136].    
2.6 Epidermal Hyperplasia 
Epidermal hyperplasia was measured using tumor adjacent, phenotypically normal skin 
sections that were stained for hematoxylin and eosin. Slides were scanned using an 
Aperio Scanscope (Leica Biosystems, Concord, Ontario, Canada). Ten images at a 20x 
magnification were taken along the sample with the investigator blinded to the identity of 
the samples. Approximately every 75 µm along the stratum corneum in each image 
epidermal thickness, as defined as extending from the epidermal-dermal junction to the 
distal edge of the stratum granulosum, and the number of nucleated epidermal cell layers 
was counted, which was then divided by the epidermal thickness to give cell density. 
2.7 Immunohistochemistry 
Staining for ki67 was performed using the paraffin-processed tumor-adjacent, 
phenotypically normal skin samples. Throughout this protocol, care was taken to prevent 
the slides from drying out. Samples were rehydrated by submerging in xylene (twice for 
15 minutes each time), 100% ethanol (once for 10 minutes), 95% ethanol in ddH2O (once 
for 10 minutes), 70% ethanol in ddH2O (once for 10 minutes), ddH2O (once for 5 
minutes). Slides were washed once prior to antigen retrieval. All washes were for 5 
minutes in 1x phosphate-buffered saline (PBS, 137 mM NaCl, 12 mM phosphate, 2.7 
mM KCl, pH 7.4), with new buffer for each wash.  
Antigen retrieval was performed in 10 mM sodium citrate buffer at pH 6 using a standard 
microwave (1200 W, NN-SA616WX, Panasonic, Kadoma, Osaka Prefecture, Japan) on 
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100% power for 3 minutes, 50% power for 5 minutes, and 30% power for 8 minutes. 
Slides were left to cool at room temperature for 30 minutes, then washed twice.  
Slides were then blocked in 3% hydrogen peroxide (30% H2O2, diluted 1:10 in 1X PBS; 
H1009, Sigma, St. Louis, MO, United States) in a vertical plastic slide holder. Slides 
were washed twice.  
The slide incubator was prepared by encircling the bottom with Kim Wipes (34120, 
Kimberly Clark, Roswell, GA, United States) soaked with ddH2O. Using a PAP pen 
(Liquid Blocker - Super PAP Pen Mini, Daido Sangyo Co., Tokyo Japan), samples were 
encircled and the slides were laid flat, sample side up, in the slide incubator. A kit was 
used (E21390, ThermoFisher, Waltham, MA, United States) to block for endogenous 
biotin. Reagent A (streptavidin) was added dropwise until the sample was covered. The 
lid was placed on the slide incubator and the slides were left to incubate at room 
temperature for 30 minutes. Slides were washed 3 times. Reagent B (biotin) was then 
added dropwise to the slides after placing them face up in the slide incubator. The lid was 
placed on and the slides incubated for 30 minutes at room temperature. The slides were 
then washed three times. 
Slides were then blocked for nonspecific binding in 3% BSA (BioShop Canada, 
Burlington, Ontario, Canada) in 1X PBS for 2 hours at room temperature in a vertical 
plastic slide holder. Samples were again encircled in PAP pen and the slides were placed 
with the samples facing up in the slide incubator. Either the ki67 primary antibody 
(1:100, ab16667, AbCam, Cambridge, MA, United States) or Rabbit IgG (1:7260, I-1000, 
Vector Labs, Burlingame, CA, United States) was applied to the sample, both of which 
are diluted in 1% BSA in 1X PBS. The samples were incubated overnight at 4oC in the 
slide incubator with damp Kim Wipes.  
The following day, slides were washed 3 times. Sections were then incubated with 
biotinylated secondary antibody (E0432, Agilent Technologies, Santa Clara, CA, United 
States) that was diluted 1:500 in 1X PBS for 2 hours at room temperature in a moist 
environment (slide incubator). Slides were washed three times.  
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Then, slides were incubated in streptavidin conjugated horseradish-peroxidase (ab7403, 
AbCam, Cambridge, MA, United States) diluted 1:2000 in 1 X PBS. Slides were washed 
once.  
The slides were then incubated with diaminobenzidine substrate (K3467, Agilent 
Technologies, Santa Clara, CA, United States). Six drops of DAB+ Chromogen was 
diluted in 2 mL of the DAB+ Substrate Buffer. This solution was applied to the slides, 
and they were incubated for 5 minutes at room temperature. Slides were washed three 
times.  
Each slide was then submerged for 30 seconds in Harris hematoxylin (10143-606, VWR, 
Radnor, PA, United States) diluted 1:1 in ddH2O. Slides were washed twice for 2 minutes 
in ddH2O. Slides were then dehydrated by submerging in 70% ethanol in ddH2O for 2 
minutes, 95% ethanol in ddH2O for 2 minutes, 100% ethanol for 2 minutes, and xylene 
twice for 1 minute each time. Slides were mounted using 2-3 drops of Cytoseal 60 (8310-
16, ThermoScientific, Waltham, MA, United States). Slides were left to dry at room 
temperature for at least 16 hours prior to scanning with the ScanScope as outlined 
previously.   
Quantitation was performed by taking ten evenly spaced images of each sample of 
phenotypically-normal, lesion adjacent skin and then by selecting one 100 µm section at 
the centre of each image. The number of ki67-positive nuclei per total nuclei was counted 
in this 100 µm area, with the investigator blinded to the identity of the samples. These 
were sorted into two groups: basal cells, defined as the keratinocytes along the stratum 
basale, and suprabasal cells, as defined as the remaining keratinocytes in the more distal 
layers. Cells positive for ki67 were expressed as a percentage of the total cells in that 
group. 
2.8 Erythema Quantitation 
The photographs taken each Monday during the chronic study were utilized to quantify 
acute erythema. Photographs were taken using the eight-megapixel camera of a Samsung 
Galaxy Grand Prime (SM-G530W, Samsung, Seoul, South Korea). These images were 
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taken between 69 and 75 hours after UVB irradiation and were quantified for the first 
four weeks. Red tones were isolated from the “Select > Color Range…” function in 
Adobe Photoshop CC 2015 (Adobe Systems, San Jose, CA, United States). From the red-
only images, five square sample images were taken per mouse per time point. Image 
sample size was standardized using the distance between the ears of the mouse as the side 
length of the square. Using Image J (NIH, Bethesda, MD, United States), a “Color 
Threshold” was applied to these sample images (Hue = 8 to 8, Saturation = 0 to 255, 
Brightness 0 to 255). The “Analyze Particles” command was then used to determine the 
area of the pixels that were positive for the presence of this specific tone red that 
correlated with acute erythema in the No Cream Control group (Figure 5). The sum of 
these areas was then divided by the total area of the sample square, giving a percentage of 
erythemal skin. Erythema was at a baseline at week 0, which corresponds to unirradiated 
skin, then peaked after one week of UVB irradiation treatment (360 mJ/cm2 total dose) 
and returned to baseline the following week.  
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Figure 5: Erythema Quantitation Optimization 
Average percent of red pixels at each week of study completed. Photographs were taken using an eight-
megapixel camera. These images were filtered to isolate red tones using Adobe Photoshop CC 2015. A 
threshold was set using Image J to highlight only a certain tone from the red-only image. This highlighted 
area was then divided by the total sample area to give the percent erythema. This tone was determined by 
comparing the unirradiated baseline redness with the redness following the first week of UVB treatment 
with a variety of reds and choosing those with the greatest difference between these two time points.  
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2.9 N-acetylglucosaminidase Activity 
β-N-Acetylglucosaminidase (NAG) activity was measured using a fluorometric assay kit 
(CS0780, Sigma, St. Louis, MO, USA). Fifty grams of whole skin (containing the 
epidermis, dermis, and hypodermis) was dissolved in 500 μL of 0.9% NaCl, 0.1% Triton 
X-100 [137] and homogenized on ice using a Dounce homogenizer . These were then 
spun at 2000 x g for 20 minutes at 4oC and 350 μL of the supernatant was stored at -20oC 
until the assay was performed. The plate was kept on ice until all components were added 
to each well, not including the stop solution.  
The standard curve was prepared by diluting 1, 2, 5, 10, 20, 40, and 80 μL of the 10 mM 
p-Nitrophenol Standard solution to a final volume of 1000 μL using Stop Solution. These 
were each performed in triplicate.  
For the positive control,1 μL of the NAG Control Enzyme was diluted in 400 μL dilution 
buffer.  In triplicate, 2 μL of this 1:400 dilution was then added to 98 μL of Substrate 
Solution for the positive control. 
Samples were kept on ice the day of the assay. In accordance with the kit’s instructions, 
10 μL of sample was combined with 90 μL of Substrate Solution, in triplicate, in a clear 
96-well plate.  
The standard curve, positive control, and samples were incubated at 37oC for 30 minutes, 
after which 200 μL of Stop Solution was added to each well of the positive control and 
the samples. Absorbance was read immediately after at 405 nm in a plate reader (Synergy 
H4 Hybrid Reader, BioTek, Winooski, VT, United States). 
2.10 Statistics 
Experimental data are presented as mean ± standard error mean (SEM). p-values were 
calculated using a two-tailed t-test. Statistical analysis was performed using Statistical 
Package for the Social Science (SPSS, Microsoft, Redmond, WA, United States).  
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Power analyses were performed using G-Power [138] using output data from SPSS. 
These calculations are based on a 95% confidence interval that is 80% powered, as well 
as equally sized treatment groups [139]. 
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Chapter 3  
3 RESULTS 
3.1 Generation of Hr-/- Ptch+/-  Mice 
To determine the effect of HA-PE treatment on UVB-induced tumor formation, it was 
first necessary to generate the KC-susceptible mice for the study. Ultraviolet light was 
chosen as the carcinogen since this is the major risk factor for human keratinocyte tumors 
[121]. The Hr -/- Ptch+/- genotype was chosen for their UVR-induced predisposition to 
increased BCC and SCC tumor load and decreased tumor latency relative to their Hr+/+ 
Ptch+/- counterparts [123]. Mice without hair also offer practical advantages such as ease 
of cream application and an easily distinguishable phenotype; in addition, there is the 
benefit that hair removal is not necessary and thus the possibility of skin irritation and 
inflammation is alleviated [140]. 
To generate the Hr-/- Ptch+/- genotype, the following pairings were performed. For the 
parental generation, haired mice carrying one non-functional allele of the Patched1 gene 
(Hr+/+ Ptch+/-) were bred with hairless mice with two functional versions of Patched1 
(Hr-/- Ptch+/+). Their F1 generation offspring were haired mice (Hr +/-) both with 
(Ptch+/-) and without (Ptch+/+) To obtain the F2 offspring, mice from the F1 generation 
with the mutant version of Patched1 (Hr+/- Ptch+/-) were crossed with one another.   
From breeding, 93 of the 464 F2 generation mice were hairless (20%), which is similar to 
the predictions from Table 1 (3/12, 25%) when not including the embryonic lethal mice. 
Hairless (Hr-/-) F2 mice, shown in white in Table 1, were visually identified as mice that 
are born with fur, which is almost completely shed by 21 days of age [140]. These mice 
were then genotyped to detect the presence of the loss of function version of Patched1 
(Ptch+/-). Results show that 6% or 27/93 of Hr-/- mice were Ptch+/-. The results are a 
third of the number that would be expected from Table 1 (2/12, 17%).  Treatment of Hr-
/- Ptch+/- mice (Figure 6) was initiated as these mice were obtained, beginning at 6 
weeks of age.  
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Figure 6 Treatment Schedule 
Figure 6 is a representation of the treatment schedule for the UVB-mediated induction of KC in Hr-/- Ptch 
+/- mice. Mice were organized into three groups: a no cream control (NCC), a vehicle cream control 
(VCC), and the HA-PE experimental group. The latter two groups received cream each day for five days of 
the week. On both Thursday and Friday, prior to cream application if required, all three groups received 
180 mJ/cm2 of UVB light. Treatment began when the mice were 6 weeks of age and continued for 26 
weeks until the mice were euthanized by CO2 24 hours after the last UVB irradiation.  
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Control and HA-PE cream were applied five days each week while UVB irradiation was 
administered twice weekly (Thursday/Friday) prior to cream application; this weekly 
treatment schedule was repeated for a total of 26 weeks. To compare experimental results 
with previously published reports of the Hr-/- Ptch+/- model of UVB-induced 
keratinocyte tumors, a no cream control (NCC) group was included using the remaining 
(n=7) available Hr-/- Ptch+/- mice. Using this breeding scheme (Figure 3), the first Hr-/- 
Ptch+/- mouse was generated in 6 months and the other 26 mice were generated in 14 
months; therefore, treatment was staggered.   
The endpoint of this study was based on the Xu et al. study, which was 26 weeks of UVB 
treatment followed by 6 weeks of observation period without further UVB exposure 
[123]. However, seven mice had to be euthanized between 15 and 24 weeks because 
lesion size had reached the maximum allowable size stipulated by the animal use 
protocol. Therefore, the design of the present study was modified to that all mice were 
euthanized at the same time e.g. after 26 weeks of treatment. The mice that were 
euthanized early were not included in the study as there was variability in how much 
UVB the mice had been exposed to in terms of the number of weeks of treatment. Thus, 
the final group sample sizes for each genotype were: n=5 for NCC; n=7 for VCC; and 
n=8 for HA-PE. Despite these losses, comparisons between the VCC and HA-PE 
treatment groups were borderline sufficiently powered at 78%, with 80% power being the 
accepted threshold [138]. Including breeding and the staggered treatment phase, this 
study took approximately 26 months.  
3.2 HA-PE and Lesion Formation 
The mice were monitored weekly to determine the time of the first palpable lesion in the 
UVB-exposed skin within the treatment area. At this point, it was not possible to 
determine which lesions were benign and which were neoplastic. Therefore, the total 
number of lesions was calculated, which included both neoplastic and non-neoplastic. 
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Table 4: Number of Mice with Lesions 
 
Mice with Lesions Total Number of Lesions 
No Cream Control (NCC) 5/5 (100%) 13 
Vehicle Cream Control (VCC) 6/7 (86%) 21 
HA-PE 4/8 (50%) 9 
All five (100%) of NCC mice and 6/7 (86%) of VCC mice developed lesions. In contrast, only half (4/8, 
50%) of the HA-PE treated mice formed lesions within the treatment area (Table 4). When this difference 
between treatment groups was calculated as binary data (i.e. lesions OR no lesions), the difference between 
the VCC and HA-PE groups was not significant (p= 0.282, Fisher’s exact test). 
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Figure 7: Lesion Load 
Upon completion of the 26-week study, mice were sacrificed and the number of lesions counted. Lesion 
load is defined as the average number of lesions per mouse. For mice without any palpable lesions, the 
input number was 0. The y-axis in Figure 7 indicates the number of lesions per mouse (load) and along the 
x-axis are the treatment groups. A No cream and vehicle cream controls. B Vehicle cream control and HA-
PE. Data above is displayed as the mean lesion load ± the standard error mean. A test for outliers was 
performed using SPSS and found two outliers, one from the no cream control group and one from the HA-
PE group; thus, these values were not included in the analysis.  
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Figure 8: Lesion Diameter 
At the end of the 26-week study, lesion size was determined by measuring the widest bisect of each lesion 
using digital calipers. Mice without lesions were not included in this analysis. In Figure 8, the lesion 
diameter in mm is displayed on the y-axis and the treatment groups are labelled in the x-axis. A No cream 
and vehicle cream controls. B Vehicle cream control and HA-PE. The lesion size is outlined as the average 
diameter ± the SEM. 
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The lesion load, or number of lesions per mouse, and size (mm) were next calculated in 
Figure 7 and Figure 8, respectively. Results in Figure 7 A and Figure 8 A, show that 
there is no significant difference in these parameters between the no cream and vehicle 
cream controls indicating that did not significantly affect lesion formation.  
However, HA-PE treatment reduced lesion load by over three-fold when compared to the 
vehicle control (Figure 7 B). Statistically, this is a strong trend that almost reached 
significance (p= 0.052). Based on the mean difference, between-groups comparison 
between the vehicle cream and HA-PE cream groups (d= 1.084), a power analysis [138] 
indicated that a sample size of twelve mice in each group would be required to assess if 
control and treatment means were significantly different at the recommended 0.80 level 
[139]. Although lesion size trended towards being 47% smaller in HA-PE treated mice 
when compared to the vehicle control, this difference was not statistically significant 
(Figure 8 B). These results show that when lesions are formed from UVB exposure, HA-
PE treatment did not affect lesion size but was underpowered, i.e. less than 80% powered, 
to show a significant difference in the average number of lesions per mouse, or lesion 
load.  
The effect of HA-PE treatment on tumor formation was next analyzed by pathological 
examination. Lesions were paraffin processed for histology sections. These were stained 
with H&E as described in Methods. Stained tissue sections were sent to The Centre for 
Phenogenomics in Toronto, Ontario to identify both the number of neoplastic lesions as 
well as the nature of benign lesions. Currently, markers of SCC and BCC are not 
available for mice and the identification of lesions as neoplastic is therefore based upon 
histological assessment by a mouse pathologist. This analysis revealed that most lesions 
were benign. 
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Table 5: Distribution of the Phenotypically Identified Lesions 
Lesion Type 
% of  
NCC 
Lesions 
NCC vs. 
VCC  
p-value 
% of  
VCC 
Lesions 
VCC vs. 
HA-PE  
p-value 
% of  
HA-PE 
Lesions 
Cysts 8% (1/13) 0.576 
14% 
(3/21) 
0.822 11% (1/9) 
Follicular 
hyperplasia 
46% 
(6/13) 
0.655 
38% 
(8/21) 
0.394 56% (5/9) 
Keratoacanthomas 0% (0/13) *0.042 
19% 
(4/21) 
0.849 22% (2/9) 
Marked dermatitis 
with cystic hair 
follicles 
54% 
(7/13) 
0.547 
33% 
(7/21) 
0.247 67% (6/9) 
Papilloma 
15% 
(2/13) 
0.303 5% (1/21) 0.154 22% (2/9) 
Subdermal keratin 
granulomas 
15% 
(2/13) 
0.619 
10% 
(2/21) 
0.355 0% (0/9) 
Table 5 above outlines the non-neoplastic lesions that were observed in the mice of this study as well as 
certain skin conditions. It is important to note that some of these can co-exist within a skin sample. For 
example, follicular hyperplasia as well as marked dermatitis can co-exist within the same sample. For this 
reason, the proportions for each group do not add up to 100%.  
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The distribution of the benign lesions amongst the treatment and control groups are 
outlined in Table 5. The frequency of most of the benign lesions did not differ in the no 
cream vs. vehicle controls. However, vehicle cream significantly increased (19%, p= 
0.042) keratoacanthoma frequency. HA-PE treatment did not decrease this effect of the 
vehicle control. The lack of differences in the different types of nonneoplastic lesions for 
HA-PE and VCC treated samples may explain why the differences in lesion load were no 
significance between these groups. Thus, I then compared the load of only neoplastic 
lesions. To compare neoplastic lesions the tumor load, or number of tumors per mouse, 
was calculated and the data are shown in Figure 9.   
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3.3 HA-PE and Tumor Formation 
 
Figure 9: Tumor Load 
Figure 9 is a comparison of the tumor load, or the number of tumors per mouse, across the three treatment 
groups. Lesions were identified as tumors based on the presence of neoplasia as characterized by a 
pathologist at The Centre for Pathology in Toronto, Ontario, Canada. On the y-axis are the number of 
tumors per mouse and the treatment groups are shown along the x-axis. A No cream and vehicle cream 
controls. B Vehicle cream control and HA-PE. Tumor load is displayed as the average number of tumors 
per mouse ± the standard error mean. 
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Tumor load was not significantly different between the two control groups (p= 0.780, 
Figure 9 A, indicating that the vehicle cream does not affect tumor formation. In 
contrast, no tumors were formed in the HA-PE treatment group which is a significant 
reduction relative to the vehicle control (Figure 9 B, p= 0.019).  
These results show that HA-PE confers resistance to UVB-induced keratinocyte tumors. 
To begin to explore the mechanism responsible for this effect, I first examined if the HA-
PE cream affected the proliferation of UVB-treated keratinocytes. Since ultraviolet light 
exposure of the epidermis causes hyperplasia, which is a precursor stage of tumorigenesis 
[141], and because HMW-HA has been reported to increase proliferation [142], the effect 
of HA-PE treatment on proliferation was explored. 
3.4 HA-PE Cream on Proliferation 
Proliferation was examined by quantification epidermal thickness, cell density of 
keratinocytes in the epidermis, and ki67 staining. In Figure 10 are the average epidermal 
thicknesses of the three treatment groups. 
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Figure 10: Epidermal Thickness 
Punch biopsies of tumor-adjacent, phenotypically-normal dorsal skin were taken after euthanization upon 
completion of the 26-week study. These sections were fixed in formalin, embedded in paraffin, and cut into 
5 μm sections. One section from each mouse was stained with hematoxylin and eosin for comparing 
histology. The epidermis is here defined as the area between the basement membrane and the distal edge of 
the stratum corneum. Ten representative images were taken of each section for each mouse, and the 
epidermal thickness was measured every 50 μm for each image, yielding the following sample groups: 
NCC, n=240; VCC, n= 336; HA-PE, n= 284. Thickness of the epidermis on the y-axis of Figure 10 and 
the treatment groups are presented on the x-axis. A No cream and vehicle cream controls. B Vehicle cream 
control and HA-PE. Epidermal thickness is expressed in μm as the average thickness ± the standard error 
mean. C Representative images of H&E-stained skin cross sections for the three treatment groups upon 
completion of the 26-week study.  
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Epidermal thickness was defined as the average distance between the basement 
membrane, or basal lamina, and the proximal edge of the stratum corneum. Significant 
differences between the epidermal thickness of the no cream and vehicle cream control 
groups were not found (Figure 10 A), indicating that the vehicle cream does not affect 
epidermal thickness. However, a significant increase in HA-PE treated epidermal 
thickness was observed when compared to the vehicle cream (Figure 10 B, 11%, p= 
0.018).  
HA-PE is a space filling extracellular molecule; therefore, the increased epidermal 
thickness could be due to expanded intercellular space resulting from HA coats and/or 
increased cell number. To assess the contribution of cell number to increased epidermal 
thickness in HA-PE treated skin, both epidermal cell density (Figure 11) and ki67 
expression in keratinocyte nuclei (Figure 12) were quantified.   
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Figure 11: Epidermal Cell Density 
Punch biopsies of tumor-adjacent, phenotypically-normal dorsal skin were taken after euthanization upon 
completion of the 26-week study. These sections were fixed in formalin, embedded in paraffin, and cut into 
5 μm sections. One representative section from each mouse was stained with hematoxylin and eosin for 
comparing histology. The epidermis is here defined as the area between the basement membrane and the 
distal edge of the stratum corneum. Along this imaginary line, cells with their intact nucleus were counted.  
Epidermal cell density is defined as the number of nucleated cells, counted perpendicular to the basement 
membrane, per μm of epidermis. Ten representative images were taken of each section for each mouse, and 
the epidermal thickness was measured every 50 μm of each image, yielding the following sample groups: 
NCC, n=240; VCC, n = 336; HA-PE, n = 284. Number of nucleated cells per μm of epidermal thickness on 
the y-axis of Figure 11 and the treatment groups are presented on the x-axis. A No cream and vehicle 
cream controls. B Vehicle cream control and HA-PE. Cell density is expressed in cells/μm as the average 
density ± the standard error mean. 
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Figure 11 shows the epidermal cells per μm, or cell density, for each treatment group. 
There was a statistically significant (7%, p= 0.019) decrease in the cell density of vehicle 
cream controls relative to the no cream controls (Figure 11 A), indicating that the vehicle 
cream by itself decreases keratinocyte density. However, HA-PE treatment was not 
significantly different from the vehicle control (Figure 11 B), demonstrating that HA-PE 
does not have an additional effect on keratinocyte density.  
ki67 is expressed during all stages of the cell cycle except for in quiescent (G0) cells 
[143] and is an acknowledged marker of proliferation. Since basal keratinocytes are 
progenitor cells of BCCs and the suprabasal population give rise to SCCs, both 
keratinocyte populations were analyzed for this experiment. Basal cells are defined as 
keratinocytes in direct contact with the basal lamina while suprabasal cells are those that 
are not. Displayed in Figure 12 are the comparisons of the percent of ki67-positive 
keratinocytes as a measure of proliferation. 
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Figure 12: Percent Proliferating Basal Cells 
Samples of tumor-adjacent, phenotypically normal skin were excised via punch biopsy, fixed in formalin, 
and embedded in paraffin. Sections were cut from these paraffin blocks and immunohistochemically 
stained for ki67. For each mouse, ten evenly dispersed images were taken of the sample and a 100 μm 
section evaluated within each image.  Basal cells (i.e. cells in contact with the basement membrane) as well 
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as suprabasal cells (i.e. cells that were not in contact with the basement membrane and were distal to the 
basal cells) were rated as either positive or negative for the presence of ki67 staining. The number of 
positive cells was divided by the number of total cells (positive and negative) and expressed as a 
percentage. The y-axis in Figure 12 is the proportion of proliferating (ki67-positive) cells expressed as a 
percent and the treatment groups are outlined along the x-axis.  Basal (A) and suprabasal (D) keratinocyte 
proliferation in the no cream and vehicle cream controls. Basal (B) and suprabasal (E) keratinocyte 
proliferation in vehicle cream control and HA-PE. The proportion of proliferating keratinocytes is 
expressed as a percent ± the standard error mean. C Representative images of ki67 staining in the epidermis 
in samples from each of the three groups.  
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There was no statistically significant difference between the no cream and vehicle cream 
control groups (basal, p= 0.322; suprabasal, p= 0.547) nor when comparing the vehicle 
cream control and HA-PE cream groups (basal, p= 0.341; suprabasal, p= 0.631). I next 
examined the effect of HA-PE on inflammation because HA-PE did not affect 
proliferation and ultraviolet light also alters the immune response [144], and epidermal 
thickening in response to UV irradiation is a result of acute inflammation [48]. 
3.5 HA-PE and Inflammation 
Following irradiation, mice develop erythema which can be used as a mechanistically 
broad-based indicator of inflammation [49]. On the Monday following UVB irradiation, 
photographs of the dorsal skin were taken and evaluated for the presence of erythema. 
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Figure 13: Quantitation of Acute Erythema Over Time 
Photographs of the dorsal region of mice were taken three days after the second UVB irradiation each 
week. The images were filtered to isolate all red tones and a specific red tone was highlighted by setting a 
threshold. This specific “erythemous” tone was selected for by generating the largest difference in the NCC 
group between the unirradiated Week 0 and the first irradiations of Week 1 (Figure 5) compared with other 
tones (not shown). The number of pixels highlighted for the presence of this specific tone of red was then 
divided by the total number of pixel in the sample area and expressed as a percent. This procedure was 
repeated after one, two, three, and four weeks of treatment for the three groups. The y-axis in Figure 13 is 
the percent of erythemous pixels and the treatment times in weeks are distributed along the x-axis. A No 
cream and vehicle cream controls. B Vehicle cream control and HA-PE. The NCC group is outlined in 
black, the VCC group in a grey, and the HA-PE in a dark blue. The acute erythema is displayed as the 
percent of erythemous pixels ± the standard error mean. 
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Figure 13 shows quantification of erythema at one to four weeks during the treatment 
regime. There are no significant differences at any of the time points between the no 
cream and vehicle cream control (Figure 13 A), demonstrating that the vehicle cream 
does not significantly alter the acute immune response relative to the no cream control as 
assessed by erythema.  
After four weeks of treatment, in Figure 13 B, there is a significant (p= 0.045), nearly 
two-fold increase in erythema in the HA-PE treated group when compared to the vehicle 
cream control group (4.2% vs. 2.3%). The differences between these two groups at the 
other time points were not statistically significant.  
Erythema is largely involved in dermal infiltration of neutrophils [145] and neutrophils 
are a sign of acute inflammation [146]. However, because the significant increase in 
erythema in the HA-PE group only occurred after 4 weeks, it is no longer acute 
inflammation and is now considered chronic [146]. Macrophage activity was determined 
next as it is a marker for chronic inflammation in UV exposed skin [147]. The level of 
macrophage activity was determined by β-N-Acetylglucosaminidase (NAG) activity, 
again using lesion-adjacent, otherwise normal skin that was taken after the completion of 
the 26-week UVB study. 
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Figure 14: NAG Enzyme Activity 
After completion of the final week of the 26-week study, mice were euthanized, and their lesions and tumor 
adjacent punch biopsies were taken for histology. The remaining dorsal skin was excised and frozen using 
dry ice in an ethanol/water bath. These samples were homogenized in a saline, Triton X-100 solution using 
a Dounce homogenizer. After centrifugation, the supernatant was stored until used in the experiment. The 
four most recently sacrificed samples (n = 4) were examined per group and run in triplicate. β-N-
Acetylglucosaminidase (NAG) in the samples reacted with the 4-Nitrophenyl N-acetyl-β-D-glucosaminide 
(NP-GlcNAc) substrate provided in each well to generate the p-nitrophenol, which is fluorescent at a basic 
pH. The increase in the fluorescence of each sample was determined and divided by the time elapsed to 
calculate the activity. The NAG activity per mg of total skin is on the y-axis in Figure 14 and the treatment 
groups are distributed along the x-axis. A No cream and vehicle cream controls. B Vehicle cream control 
and HA-PE. Activity is shown as the average NAG activity per mg ± the standard error mean. 
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The no cream and vehicle cream control groups (Figure 14 A) exhibited similar NAG 
activity and there was no significant difference (p= 0.975), illustrating that the vehicle 
cream has no effect on chronic inflammation. 
There is a 55% increase in NAG activity in the HA-PE group relative to the vehicle 
cream control group (Figure 14 B) and this difference is statistically significant (p= 
0.018); this result provides evidence that HA-PE has a stimulating effect on macrophage 
activity unaffected by vehicle cream treatment.  
Therefore, HA-PE treatment produced a significant reduction in UVB-induced neoplasms 
and this reduction was associated with an increase in macrophage activity.  
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Chapter 4  
4 DISCUSSION 
4.1 HA-PE Decreases Neoplastic Tumor Formation 
These experiments show that HA-PE prevents detectable tumor formation, in addition to 
decreasing total lesions by 50%, relative to the vehicle cream control in the Hr-/- Ptch+/- 
mouse model of UVB induced keratinocyte carcinogenesis. The topical application of 
HA-PE has converted a UVB-induced KC-susceptible mouse model into the resistant 
phenotype seen in the more resistant naked mole rat.  
Hašová et al. have previously linked HMW HA to protection from UVB-induced pro-
inflammatory cytokine release. In this study, the addition of >500 kDa HA added to 
human keratinocytes in culture reduced UVB-stimulated IL-6, IL-8, and TGFβ1 amongst 
other pro-inflammatory cytokines [30]. In the same study, HMW-HA also significantly 
suppressed the decrease in cell viability resulting from UVB irradiation [30].  
Additionally, naked mole rat fibroblasts were more sensitive than mouse fibroblasts to 
UVC (254 nm) and H2O2 [148]. While UVC is not as biologically relevant due to its 
limited penetrance through the ozone layer, it still suggests that this mechanism is more 
complex than can be conveyed in a monoculture of skin fibroblasts.  
HA secreted by skin fibroblasts in humans and mice ranges in size from 0.5 to 3 MDa in 
size but due to a two amino-acid substitution in the otherwise conserved HAS2 leads to 
HA of 6 to 12 MDa in size from these cells [106]. Naked mole rats also display a self-
regulated growth regulation termed early contact inhibition (ECI), the effects of which 
are abrogated by treatment of these skin fibroblast cultures with hyaluronidase, the 
enzyme that degrades HA [149]. The Gorbunova and Seluanov group showed that the 
cell cycle inhibitor p16INK4a is necessary for ECI and is upregulated in the presence of HA 
[149].  
Relative to mice, naked mole rats have increased bone marrow HA and hematopoietic 
stem cells (HSCs). These stem cells have also been shown to be more resistant to 
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genotoxic stress. Transgenic mice expressing naked mole rat HAS2 have elevated HA 
and HSCs in their bone marrow relative to control mice [150].  
Blind mole rats, which also show extraordinary longevity for their size, living up to 20 
years compared to the 4-year lifespan of mice [151]. Blind mole rats also produce HMW 
HA in a similar way to naked mole rats but do not demonstrate ECI; rather, they will 
undergo mass cell death upon reaching high densities [152].  
In uninjured skin, HMW HA predominates in the skin and has anti-inflammatory effects 
such as reducing the production of inflammatory cytokines [153]. UVB breaks off the 
bonds of HA, degrading HMW HA to LMW HA; this is either directly through 
absorption or through the production of ROS [154]. This LMW HA activates dendritic 
cells such as the Langerhans cells in the skin [155] as well as promotes the release of 
proinflammatory cytokines [156]. It is possible that this HMW HA is protective in a 
signaling role but not with other fibroblasts but in interaction with the immune system.  
It has been postulated that HA stimulates the immune system based on size, but not in a 
linear way [157]. Hyaluronan accumulation is a signal that induces epithelial to 
mesenchymal transition [158]. HA levels in cancer epithelium and peritumoral stroma 
relate to progression and unfavourable outcome [159]. HA has also been shown to 
actively participate in cancer [160]. 
4.2 Effect of HA-PE on Inflammation 
In my experiments, HA-PE significantly increased erythema at 4 weeks and β-N-
acetylglucosaminidase at 26 weeks relative to the vehicle cream control group.  
NAG is a biomarker for total macrophage activity; however, two subpopulations of 
macrophages predominate: M1 and M2, involved in classic and alternative activation, 
respectively [161]. M1 macrophages promote production of pro-inflammatory cytokines 
and nitrogen and oxygen intermediates, as well as Th1 responses (REF); M2 
macrophages are involved in immune regulation and have been linked to tumor 
promotion [162, 163].  
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HA-PE has been shown previously to not alter local or systemic inflammation when 
compared to HA- or vehicle- controls when inflammation was otherwise unstimulated 
[108]. However, the HMW HA in the HA-PE formulation was presumably broken down 
to LMW HA by ultraviolet light, ROS, or hyaluronidases from UVR [66]. Enhanced 
ECM degradation, such as with HA, disturbs ECM homeostasis and signals danger to the 
innate immune system, activating the inflammasome, including macrophages, via TLR2 
and TLR4 [164, 165].  
Combination therapy is common in current cancer treatment and pertains not only to 
multiple chemotherapeutic drugs but also other treatment modalities such as 
immunotherapy. However, chemotherapy has the potential to suppress actions of the 
immune system and thus interfere with the efficacy of immunotherapy when used in 
combination [166]. Immunotherapy to activate tumor associated  macrophages (TAMs) 
and repolarize from the M2 pro-tumor type to the M1 anti-tumor type has been shown to 
reduce tumor volume as well as increase survival time in mouse xenograft models of 
melanoma and neuroblastoma [167]. It is possible that the utilization of HA-PE shifts 
macrophages from an M2 to an M1 polarization.   
4.3 Effect of HA-PE on Hyperplasia 
HA-PE significantly increased epidermal thickness relative to the vehicle cream control 
and this was verified to not be due to a decrease in cell density. HA is hygroscopic and an 
excellent space filler [168]. Previously, topical application of the HA-PE cream to wild-
type CB57BL/6 shaved mice showed a significant increase in epidermal thickness 
relative to vehicle cream controls as early as after 5 subsequent once-daily cream 
applications [108]. Though the mice in this study were sacrificed 24 hours after the final 
cream application, Symonette et al. also showed using fluorescent labelling that HA-PE 
stays in the epidermis 24 hours after cream application [108]. In addition, UVB light 
causes an increase in the activity of the hyaluronan synthases (Rauhala et al., 2013) 
which could contribute to an increase in keratinocyte coats and thus epidermal thickness.  
In the actively proliferating basal regions of the epidermis, the concentration of HA is 
very high; this is to be expected as basal keratinocytes are in a both undifferentiated and 
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proliferative state [169-171]. UVB light causes an increase of the three hyaluronan 
synthases [168], and increased HA synthesis activity is often found epidermal hyperplasia 
in mice [37].  
However, there was a trend toward decreased ki67 staining in both the basal and 
suprabasal layers when comparing HA-PE to the vehicle cream control. HA-PE has been 
previously shown to stimulate keratinocyte proliferation relative to unmodified HA or 
vehicle controls in C57BL/6 mouse skin [108]. Keratinocyte proliferation has previously 
been shown to increase in response to topical HA, but only 50 - 400 kDa HA [172]. In 
acute UVB experiments, an increase in proliferation (ki67) was detected on day 2 post-
UVR, before epidermal hyperplasia reached a peak [66]. However, drastic molecular size 
shift in HA was observed on day 3 after UVR, when epidermal thickness tends to 
decrease, suggesting the shift triggers the differentiation of keratinocytes [66]. The 
increase in epidermal thickness is also not likely due to cell size, which correlates to 
proliferative activity which was not altered as indicated by ki67 staining. 
4.4 Use of Vehicle Cream as a Control 
Upon completion of this study, 3/7 or 46% of the vehicle cream control group developed 
at least one neoplastic lesion, with one mouse developing two; in contrast, 60% of 3/5 of 
the no cream control mice had developed tumors and 100% had developed lesions. This 
is less than Xu et al. where the model was adapted from, as they found that each mouse 
had at least one tumor on average at 22 weeks, which corresponds to the no cream control 
(NCC) group with respect to treatment conditions [123].  
Relative to the no cream control, the vehicle cream did significantly decrease the cell 
density in the epidermis. There was a trend towards decreased acute inflammation as 
evidenced by erythema in the vehicle control relative to the no cream control but this 
difference was not significant. There was no change in the NAG activity in the vehicle 
cream control group relative to the no cream control group. 
The vehicle cream significantly increased the formation of keratoacanthomas (p= 0.042) 
relative to the no cream control group, and HA-PE did not significantly affect the 
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formation of this type of lesion (p= 0.849). Keratoacanthomas have clinical and 
histological similarities to well differentiated SCC, and are characterized by rapid onset, 
progression, and regression within months [173]. This could be due to the presence of 
sodium hyaluronate (i.e. HA) in the vehicle cream control; commercial creams tend to 
have low molecular weight (LMW HA) for their increased skin penetrance relative to 
greater molecular weights [174].   
4.5 Summary and Future Studies 
4.5.1 Limitations 
The greatest limitation in this experiment was time: it took 26 months alone to complete 
the experiment, not including further analysis of tissue. Maintaining this schedule led to 
smaller sample sizes per group. Related to sample size, a HA alone and PE alone control 
would be ideal for this experiment. 
4.5.2 Future Work 
Tumors have been submitted for further analysis by Dr. Geoffrey Wood of the University 
of Guelph to determine tumor type specifically. However, given the apparent lack of 
tumors at 26 weeks in the HA-PE treated group, it is safe to conclude that this agent 
slows the formation of more than one type of neoplasia. 
Using the same phenotypically normal skin samples, I would perform co-
immunofluorescence for CD11c and YM1, which are markers for M1 and M2 
macrophages, respectively [161]. Given the lack of tumorigenesis in the model, I would 
expect to see that there is an increase in M1 macrophages and would verify this by 
comparing iNOS activity, using the skin samples homogenized for the NAG assay, as this 
is also a marker of M1 macrophages [161].  
One short-term mouse studies I would like to perform would be testing HA-PE in UVB-
induced KC while treating the mice with inhibitors of IL1β (recombinant IL1ra) [175] to 
determine begin to elucidate the involvement, if any, of the NLRP3 inflammasome in 
HA-PE-mediated cancer prevention. CD44 has been implicated as the receptor required 
for the stimulation of the NLRP3 inflammasome using CD44-deficient mice [176]. Long 
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term, I would like to test the UVB-induced KC via HA-PE application on a CD44-/- 
background in mice [177]. I expect that the KO mice would show the same tumor 
formation as no cream control WT mice. CD44 null mice showed a significantly reduced 
IL1β release compared to WT counterparts in peritoneal macrophages, as well the use of 
a CD44-antibodies in a WT cell line produced similar results indicating that CD44 is 
required for HA-dependent IL1β [176] and thus I would also like to do acute studies on 
this background measuring for changes in IL1β. 
4.5.3 Summary 
In summary, no tumors were observed after HA-PE treatment in this model of KC 
susceptibility. Given the effects of HA-PE relative to the vehicle control on NAG 
activity, HA-PE may be acting via the photodegradative products to HA-PE, stimulating 
the NLRP3 inflammasome. This is in keeping with the blind mole rat model of resistance, 
as NLRP3 has also been shown, when activated, to upregulate in interferon-β [178] 
which blind mole rat fibroblasts secrete in response to increased cell density [101, 152]. 
Future work will be to validate the NLRP3 inflammasome as the mechanism of HA-PE in 
preventing tumorigenesis.  
The lack of efficacy of current sunscreens suggests the need for new preventative topical 
agents. In my experiments, HA-PE prevented UVB-induced tumor formation in the skin 
of mice. This result raises the possibility that HA-PE could serve as a possible treatment 
for the prevention of UVR-induced KCs in the general human population, as well as 
those at higher risk due to immune suppression. 
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